Research Papers:

NAMPT overexpression induces cancer stemness and defines a novel tumor signature for glioma prognosis

Antonio Lucena-Cacace, Daniel Otero-Albiol, Manuel P. Jiménez-García, Javier Peinado-Serrano and Amancio Carnero _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:99514-99530. https://doi.org/10.18632/oncotarget.20577

Metrics: PDF 1897 views  |   HTML 4678 views  |   ?  


Antonio Lucena-Cacace1,2, Daniel Otero-Albiol1,2, Manuel P. Jiménez-García1,2, Javier Peinado-Serrano1 and Amancio Carnero1,2

1Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del Rocio, Universidad de Sevilla, Consejo Superior de Investigaciones Cientificas, Sevilla, Spain

2CIBER DE CANCER, Instituto de Salud Carlos III, Madrid, Spain

Correspondence to:

Amancio Carnero, email: [email protected]

Keywords: NAMPT, cancer initiating cell, gene signature, glioma, glioblastoma

Received: June 22, 2017     Accepted: July 25, 2017     Published: August 28, 2017


Gliomas are the most prevalent primary malignant brain tumors associated with poor prognosis. NAMPT, a rate-limiting enzyme that boosts the nicotinamide adenine dinucleotide (NAD) regeneration in the salvage pathway, is commonly expressed in these tumors. NAD metabolism is required to maintain tissue homeostasis. To maintain metabolism, cancer cells require a stable NAD regeneration circuit. However, high levels of NAD confer resistance to therapy to these tumors, usually treated with Temozolomide (TMZ). We report that NAMPT overexpression in glioma cell lines increases tumorigenic properties controlling stem cell pathways and enriching the cancer-initiating cell (CIC) population. Furthermore, NAMPT expression correlated with high levels of Nanog, CD133 and CIC-like cells in glioblastoma directly extracted from patients. Meta-analysis reveals that NAMPT is also a key factor inducing cancer stem pathways in glioma cells. Furthermore, we report a novel NAMPT-driven signature which stratify prognosis within tumor staging. NAMPT signature also correlates directly with EGFR positive and IDH negative tumors. Finally, NAMPT inhibition increases sensitivity to apoptosis in both NAMPT-expressing cells and tumorspheres. Therefore, NAMPT represents a novel therapeutic target in Glioma progression and relapse.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20577